Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Zhaoling Zou"'
Publikováno v:
Drug Design, Development and Therapy
Background Over the past few decades, cyclophosphamide (CP) has been extensively used as a broad-spectrum alkylating agent for the treatment of various cancers and solid tumors. However, the therapeutic actions on CP are not limited to only cancer ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19ff5dd25d96a996b6af4166ee78bfab
https://pubmed.ncbi.nlm.nih.gov/34703213
https://pubmed.ncbi.nlm.nih.gov/34703213
Autor:
Jiexian Ma, Xiaohua Wang, Zhaoling Zou, Mixue Xie, Jingsheng Hua, Youdao Liang, Min Wu, Ruyu Yang, Yingwei Hu, Yu Xu, Yanhui Xie, Xiujin Ye, Xiaoqin Wang
Publikováno v:
Clinical lymphoma, myelomaleukemia. 21(10)
Background Decitabine are used in the treatment of myelodysplastic syndrome (MDS), but none trials reported overall survival improvement. Methods High-risk MDS and MDS transformed AML (sAML) patients (IPSS-R > 4.5, age above 60 years) in 6 medical ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d84253ebb600030d9d1d7059ca16579a
https://pubmed.ncbi.nlm.nih.gov/34226168
https://pubmed.ncbi.nlm.nih.gov/34226168
Publikováno v:
Journal of Healthcare Engineering, Vol 2021 (2021)
Journal of Healthcare Engineering
Journal of Healthcare Engineering
Objective. To explore the safety of anlotinib capsules combined with the PD-1 inhibitor (camrelizumab) in the third-line treatment of advanced non-small-cell lung cancer (NSCLC) and their effect on serum tumor markers. Methods. 88 patients with advan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7322959e918eb7dba08b643d9dd57869
[P53 abnormality and clinical prognosis of leukemia patients with complex chromosomal abnormalities]
Publikováno v:
Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics. 27(1)
To investigate the p53 deletion in leukemia patients with complex chromosomal abnormalities (CCA) and the clinical significance.The p53 deletion status of 38 leukemia cases with CCA and 24 cases without CCA were analyzed by interphase fluorescence in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::91c50aff6d958b8c0aa75db81ec34d6a
https://pubmed.ncbi.nlm.nih.gov/20140875
https://pubmed.ncbi.nlm.nih.gov/20140875